Cortechs.ai | A word from the CEO: 2015 in review

A word from the CEO: 2015 in review

NeuroQuant_2015_infographic1.png2015 was an incredible year for Cortechs.ai, with the team continuing to build on the momentum we started in 2014. During the year, we experienced remarkable growth in our business, added many significant new customers and expanded our strategic business partnerships.

With over 100,000 brains analyzed using NeuroQuant, it is exciting to watch the growth indicating an increased acceptance and realized importance of using quantitative imaging for the assessment of neurological disorders. During 2015, we established NeuroQuant as the most proven and most accurate quantitative imaging solutions and enjoyed worldwide support within hospitals, universities, radiology centers, clinical and research practices and military hospitals. These facilities see and understand the value of NeuroQuant’s volumetric measurements of subcortical structures aiding in the assessment of a variety of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and brain development.

In the middle of 2015 we released NeuroQuant 2.0, providing significant additions and improvements, among them, new and improved output reports for ages 3 years to 100, the advanced Dynamic Atlas™ segmentation and registration technology, increased accuracy and precision of brain segmentation, and operating system independence. Toward the end of 2015, we expanded NeuroQuant 2.0 to include productivity enhancing capabilities such as the use of parallel imaging on GE, Philips and Siemens 3.0 T scanners, providing faster scan times, the addition of Toshiba Titan 3T scanner compatibility and PowerScribe 360 integration. Click on the infographic to the right to see a better overall picture of 2015’s developments

With these expanded capabilities NeuroQuant continues to be the paramount solution for the assessment of neurological conditions. From brain development to Alzheimer’s, multiple sclerosis, epilepsy and brain trauma, NeuroQuant helps enhance the quality of patient care. As always, we welcome feedback and ideas for improvement from anybody that wants to share it with us.

2015 was a great year, and we are thrilled to see what unfolds for 2016. Stay tuned – more exciting developments are happening and we look forward to sharing them with you!

Guri Stark, CEO
Cortechs.ai

More Resources

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage

09/02/2025

Maximizing the Value of Prostate MRI for the Urologist

Even with expert radiologists or AI models at hand, the challenge remains: how can urologists improve seeing and interpreting cancer?

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.
Scroll to Top